SCHEMBL7121865

SCHEMBL7121865

c1cc(Nc2nccc3c(-n4cccc4)cccc23)cc(-n2cncn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
GRM4 Q14833 1/20 0.36
CYP2A6 P11509 1/20 0.36
MAPK10 P53779 1/20 0.35
EGFR P00533 5/20 0.34
S1PR1 P21453 1/20 0.34
PDGFRB P09619 3/20 0.33
ABL1 P00519 1/20 0.33
BCR P11274 1/20 0.33
SRC P12931 1/20 0.33
PDGFRA P16234 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCD Q05655 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7120237 0.78 BRD4 (0.40) BRD4CREBBPGRM4CYP2A6MAPK10
SCHEMBL6804253 0.74 BRD4 (0.45) BRD4CREBBPGRM4CYP2A6MAPK10
SCHEMBL7126101 0.71 BRAF (0.36) EGFRMAPTALDH1A1HPGDTSHR
SCHEMBL6800200 0.70 MAPT (0.47) BRD4CREBBPCYP2A6EGFRKDM4E
SCHEMBL7124011 0.69 ABL1 (0.49) CYP2A6EGFRPDGFRBABL1BCR
SCHEMBL7160086 0.69 RIPK2 (0.41) EGFRPDGFRBKDM4EALDH1A1LMNA
SCHEMBL7128731 0.67 ABL1 (0.53) PDGFRBABL1BCRSRCPDGFRA
SCHEMBL1020544 0.67 CYP2A6 (0.49) BRD4CREBBPCYP2A6MAPK10S1PR1
SCHEMBL7117333 0.66 ABL1 (0.54) CYP2A6EGFRPDGFRBABL1BCR
SCHEMBL11926858 0.65 CYP2A6 (0.62) BRD4CREBBPCYP2A6MAPK10HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 BRD4 2902/4885CREBBP 4139/4885GRM4 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.